From the Editor’s desk...
EASL LiverTree™, Journal of Hepatology, 193218
SCARB1 variants and HCV infection: Host susceptibility is lost in translation
EASL LiverTree™, Journal of Hepatology, 193219
Cytotoxic bilirubin metabolites overlooked so far
EASL LiverTree™, Milan Jirsa, 193220
Controlling liver cancer mortality on a global scale: Still a long way to go
EASL LiverTree™, Journal of Hepatology, 193221
O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC
EASL LiverTree™, Journal of Hepatology, 193222
Coffee and tea breaks for liver health
EASL LiverTree™, Journal of Hepatology, 193223
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses
EASL LiverTree™, Neeru Bhardwaj, 193224
Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load
EASL LiverTree™, Thomas von Hahn, 193225
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy
EASL LiverTree™, Frank Tacke, 193226
Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990–2014
EASL LiverTree™, Daniela Van Santen, 193227
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
EASL LiverTree™, Paul Kwo, 193228
Impact of higher-order heme degradation products on hepatic function and hemodynamics
EASL LiverTree™, Michael Bauer, 193229
Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma
EASL LiverTree™, Miroslaw Kornek, 193230
Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma
EASL LiverTree™, Jian Zhou, 193231
Global trends and predictions in hepatocellular carcinoma mortality
EASL LiverTree™, Carlo La Vecchia, 193232
O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress
EASL LiverTree™, Jun Yu, 193233
Hepatobiliary transport kinetics of the conjugated bile acid tracer C-CSar quantified in healthy humans and patients by positron emission tomography
EASL LiverTree™, Michael Soerensen, 193234
CD44 is a key player in non-alcoholic steatohepatitis
EASL LiverTree™, Philippe Gual, 193235
Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study
EASL LiverTree™, Sarwa Darwish Murad, 193236
Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload
EASL LiverTree™, Satdarshan (Paul) Monga, 193238
Non-invasive evaluation of portal hypertension using ultrasound elastography
EASL LiverTree™, Annalisa Berzigotti, 193240
Current therapeutic approaches for HBV infected patients
EASL LiverTree™, Patrick Kennedy, 193241
Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals
EASL LiverTree™, Hamid Hasson, 193242
Should anti-LKM1 be routine for work-up of elevated liver enzymes?
EASL LiverTree™, Deepak Agrawal, 193243
Reply to: “Should anti-LKM1 be routine for work-up of elevated liver enzymes?”
EASL LiverTree™, Elliot Tapper, 193244
Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
EASL LiverTree™, Jason Grebely, 193245
Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”
EASL LiverTree™, Ruth Zimmermann, 193246
Reply to: “In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals”
EASL LiverTree™, Bettina Langhans, 193248
Carvedilol and survival in cirrhosis with ascites: A cognitive bias?
EASL LiverTree™, Anderson Brito-Azevedo, 193249
Reply to: “Carvedilol and survival in cirrhosis with ascites: A cognitive bias?”
EASL LiverTree™, Rohit Sinha, 193250
Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment
EASL LiverTree™, Sofie Hallager, 193251
Reply to: “Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment”
EASL LiverTree™, Savino Bruno, 193252
Erratum to “Human liver regeneration in advanced cirrhosis is organized by the portal tree” [J Hepatol 66 (2017) 778–786]
EASL LiverTree™, Sándor Paku, 193253
From the Editor’s desk...
EASL LiverTree™, Richard Moreau, 193183
How to eliminate HCV infection by antiviral treatment
EASL LiverTree™, Natasha Martin, 193184
Mesenchymal stromal cells for immunomodulatory cell therapy in liver transplantation: One step at a time
EASL LiverTree™, Pau Sancho-Bru, 193185
Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
EASL LiverTree™, Olivier Soubrane, 193186
Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAH randomized controlled trial
EASL LiverTree™, Markus Peck-Radosavljevic, 193187
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015
EASL LiverTree™, Ruth Zimmermann, 193188
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort
EASL LiverTree™, Linda Wittkop, 193189
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites
EASL LiverTree™, Rohit Sinha, 193191
Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I–II, open-label, clinical study
EASL LiverTree™, Olivier Detry, 193192
Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases
EASL LiverTree™, Jean-Nicolas Vauthey, 193193
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma
EASL LiverTree™, calogero camma, 193194
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
EASL LiverTree™, Jesus Bañales, 193195
Reversibility of chemotherapy-related liver injury
EASL LiverTree™, Luca Viganò, 193196
Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis
EASL LiverTree™, Gonzalo Sapisochin, 193197
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice
EASL LiverTree™, Peter Fickert, 193199
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD
EASL LiverTree™, Panu Luukkonen, 193201
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor
EASL LiverTree™, Robert Fontana, 193202
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
EASL LiverTree™, Monika Galle, 193204
Diagnosis and treatment of ascites
EASL LiverTree™, Alexander Gerbes, 193205
Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination
EASL LiverTree™, Silvia Vilarinho, 193206
Serum HBsAg kinetics in clinical prediction
EASL LiverTree™, Yun-Fan Liaw, 193207
Reply to: “Serum HBsAg kinetics in clinical prediction”
EASL LiverTree™, Henry LY Chan, 193208
Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”
EASL LiverTree™, Josep M. Llovet, 193210
Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
EASL LiverTree™, Quirino Lai, 193211
Reply to: “Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?”
EASL LiverTree™, Marc Bilodeau, 193212
Adding embolization to TIPS implantation: A better therapy to control bleeding from ectopic varices?
EASL LiverTree™, Giovanni Perricone, 193213
Reply to: “Adding embolization to TIPS implantation: A better therapy to control bleeding from ectopic varices?”
EASL LiverTree™, Journal of Hepatology, 193214
HBV markers for HCC prediction: Three heads are better than two?
EASL LiverTree™, Journal of Hepatology, 193215
Reply to: “HBV markers for HCC prediction: Three heads are better than two?”
EASL LiverTree™, Journal of Hepatology, 193216
The International Liver Congress. Paris, France, 2018.
EASL LiverTree™, Journal of Hepatology, 193217
Best of EASL Monothematic Conference: Cholangiocytes in health and disease: from basic science to novel treatments
EASL LiverTree™, Dr. J.M. Banales, Prof. Dr. P.L. Jansen, Prof. N.F. Larusso, Dr. M. Marzioni, 186698
Concluding Remarks
EASL LiverTree™, Peter L Jansen, 183780
Principles of value based medicine as applied to cholangiopathies
EASL LiverTree™, Mario Strazzabosco, 183778
Cell transplantation
EASL LiverTree™, Domenico Alvaro, 183776
Cholestatic drug induced liver injury
EASL LiverTree™, Raúl J Andrade, 183775
The future of therapy for cholangiopathies
EASL LiverTree™, Michael Trauner, 183774
Assessment of hepatic secretion function with 11C-cholylsarcosine PET/CT
EASL LiverTree™, Michael Soerensen, 183773
Biomarkers for cholangiopathies and cholangiocarcinoma
EASL LiverTree™, Daniel Gotthardt, 183772
The anti-inflammatory receptor TREM-2 protects the liver from cholestatic injury in mice
EASL LiverTree™, Aitor Esparza-Baquer, 177617
CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma
EASL LiverTree™, Dalong Sun, 177618
Fluoroscopically guided biopsies do not seem to improve cancer detection rates in patients with biliary strictures undergoing brush cytology during ERCP
EASL LiverTree™, Daniela Reis, 177619
Hepatoprotective effect of S-Adenosyl L-Methionine (SAMe) in oxidative stress: in vitro study on hepatocytes and cholangiocytes
EASL LiverTree™, Ewa Kilanczyk, 177620
Anti-apoptotic role of c-FLIP in human cholangiocarcinoma: activation of Fas/FasL pathway
EASL LiverTree™, Gianluca Carnevale, 177621
Epigentic profiling of premalignant and malignant stages of cholangiocarcinoma
EASL LiverTree™, Ursula J. Lemberger, 177623
The endoscopist and malignant and non-malignant biliary obstructions
EASL LiverTree™, Stephen Pereira, 183769
Cholangiocarcinoma: Epidemiological trends and clinical management
EASL LiverTree™, Shahid A Khan, 183768
Genetics of familial cholangiopathies
EASL LiverTree™, Frank Lammert, 183767
Cholangiopathies in children
EASL LiverTree™, Richard Thompson, 183766
Tumour stroma in cholangiocarcinoma: A novel therapeutic target
EASL LiverTree™, Joachim C. Mertens, 183763
Chemoresistance and chemosensitization in cholangiocarcinoma
EASL LiverTree™, Jose J.G. Marin, 183762
Stem cell origin of cholangiocarcinoma
EASL LiverTree™, Tania Roskams, 183761
BBA AWARD
EASL LiverTree™, Ronald Oude Elferink, 184937
Target molecules in cholangiocarcinoma cells
EASL LiverTree™, Gregory Gores, 183760
Identification of tumour suppressive and oncogenic microRNAs in gallbladder carcinoma
EASL LiverTree™, Benjamin Goeppert, 177610
Biliary micorhamartomas (Von-Meyenburg complexes) are frequently associated with intrahepatic and hilar cholangiocarcinomas in liver
EASL LiverTree™, Joanna Gibson, 177611
The positive effect of exosomes on epithelial-mesenchymal transition through hedgehog signalling in cholangiocarcinoma cells
EASL LiverTree™, Özlem Kücükoglu, 177612
ATP Binding Cassette B4 (ABCB4) related disease – from genetics to phenotypic variability: a case series
EASL LiverTree™, Pedro Marques da Costa, 177613
Liver transplantation in patients with hilar cholangiocarcinoma- single center experience
EASL LiverTree™, Ana Ostojic, 177614
Liver progenitor cells significantly contribute to hepatocyte pool in chronic liver injury and cirrhosis: a kinetic study in mice
EASL LiverTree™, Rita Manco, 177615
Preliminary results from application of image processing tools and quantitative analysis of MRCP datasets of various aetiologies
EASL LiverTree™, Andy McKay, 177616
Bile acid homeostasis and immunity of the liver
EASL LiverTree™, Christoph Schramm, 183756
Mucosal immunity of the biliary tree in normality and disease
EASL LiverTree™, David Adams, 183754
The bile acid receptor TGR5 regulates paracellular permeability and protects the liver through an impact on the tight junction protein JAM-A
EASL LiverTree™, Grégory Merlen, 183751
Chronic treatment with clinic dose of metformin completely reverses the epithelial to mesenchymal transition (EMT) in human intrahepatic cholangiocarcinomas (iCCAs) by activated AMPK / Foxo3a pathway
EASL LiverTree™, Sabina Di Matteo, 183750
Inhibition of Src tyrosine kinase restores CFTR function in cystic fibrosis cholangiocytes derived from human induced pluripotent stem cells (iPSC) and improves the response to CFTR potentiators and correctors used in therapy
EASL LiverTree™, Romina Fiorotto, 183749
The role of ageing in the pathophysiology of the biliary epithelium: identification of a molecular profile
EASL LiverTree™, Luca Maroni, 183748
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
EASL LiverTree™, Ander Arbelaiz, 183747